Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for NBIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 401.80M
March 31, 2026 406.20M
December 31, 2025 415.30M
September 30, 2025 428.40M
June 30, 2025 439.10M
March 31, 2025 447.50M
December 31, 2024 455.10M
September 30, 2024 251.40M
June 30, 2024 256.20M
March 31, 2024 252.90M
December 31, 2023 428.40M
September 30, 2023 255.80M
June 30, 2023 258.80M
March 31, 2023 259.90M
December 31, 2022 262.90M
September 30, 2022 265.80M
June 30, 2022 268.60M
March 31, 2022 480.20M
December 31, 2021 440.40M
September 30, 2021 437.10M
June 30, 2021 435.30M
March 31, 2021 429.50M
December 31, 2020 412.30M
September 30, 2020 508.00M
June 30, 2020 503.80M
Date Value
March 31, 2020 499.70M
December 31, 2019 495.56M
September 30, 2019 478.07M
June 30, 2019 464.65M
March 31, 2019 460.58M
December 31, 2018 388.50M
September 30, 2018 383.65M
June 30, 2018 378.88M
March 31, 2018 374.21M
December 31, 2017 369.62M
September 30, 2017 365.11M
June 30, 2017 360.68M
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Amarin Corp. Plc 5.255M
Liquidia Corp. 182.90M
Incyte Corp. 32.68M
Halozyme Therapeutics, Inc. 2.147B
Iovance Biotherapeutics, Inc. 43.33M